Search

Your search keyword '"Dufies, Maeva"' showing total 26 results
Start Over Author "Dufies, Maeva" Publication Year Range Last 3 years
26 results on '"Dufies, Maeva"'

2. A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR+CXCL-CXCR1/2 Pathway Inhibitor

Author

Grytsai, Oleksandr, primary, Dufies, Maeva, additional, Le Du, Julie, additional, Rastoin, Olivia, additional, Pires Gonçalves, Leticia Christina, additional, Mateo, Lou, additional, Lacas-Gervais, Sandra, additional, Cao, Yihai, additional, Demange, Luc, additional, Pagès, Gilles, additional, Benhida, Rachid, additional, and Ronco, Cyril, additional

Published
2024
Full Text
View/download PDF

3. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

Author

Montemagno, Christopher, primary, Jacquel, Arnaud, additional, Pandiani, Charlotte, additional, Rastoin, Olivia, additional, Dawaliby, Rosie, additional, Schmitt, Thomas, additional, Bourgoin, Maxence, additional, Palenzuela, Héliciane, additional, Rossi, Anne-Laure, additional, Ambrosetti, Damien, additional, Durivault, Jerome, additional, Luciano, Frederic, additional, Borchiellini, Delphine, additional, Le Du, Julie, additional, Gonçalves, Leticia Christina Pires, additional, Auberger, Patrick, additional, Benhida, Rachid, additional, Kinget, Lisa, additional, Beuselinck, Benoit, additional, Ronco, Cyril, additional, Pagès, Gilles, additional, and Dufies, Maeva, additional

Published
2024
Full Text
View/download PDF

5. Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression

Author

Cooley, Lindsay S., Rudewicz, Justine, Souleyreau, Wilfried, Emanuelli, Andrea, Alvarez-Arenas, Arturo, Clarke, Kim, Falciani, Francesco, Dufies, Maeva, Lambrechts, Diether, Modave, Elodie, Chalopin-Fillot, Domitille, Pineau, Raphael, Ambrosetti, Damien, Bernhard, Jean-Christophe, Ravaud, Alain, Négrier, Sylvie, Ferrero, Jean-Marc, Pagès, Gilles, Benzekry, Sebastien, Nikolski, Macha, and Bikfalvi, Andreas

Published
2021
Full Text
View/download PDF

6. Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma

Author

Dufies, Maeva, Verbiest, Annelies, Cooley, Lindsay S., Ndiaye, Papa Diogop, He, Xingkang, Nottet, Nicolas, Souleyreau, Wilfried, Hagege, Anais, Torrino, Stephanie, Parola, Julien, Giuliano, Sandy, Borchiellini, Delphine, Schiappa, Renaud, Mograbi, Baharia, Zucman-Rossi, Jessica, Bensalah, Karim, Ravaud, Alain, Auberger, Patrick, Bikfalvi, Andréas, Chamorey, Emmanuel, Rioux-Leclercq, Nathalie, Mazure, Nathalie M., Beuselinck, Benoit, Cao, Yihai, Bernhard, Jean Christophe, Ambrosetti, Damien, and Pagès, Gilles

Published
2021
Full Text
View/download PDF

7. A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma

Author

Montemagno, Christopher, primary, Durivault, Jérôme, additional, Gastaldi, Cécile, additional, Dufies, Maeva, additional, Vial, Valérie, additional, He, Xingkang, additional, Ambrosetti, Damien, additional, Kamenskaya, Anna, additional, Negrier, Sylvie, additional, Bernhard, Jean‐Christophe, additional, Borchiellini, Delphine, additional, Cao, Yihai, additional, and Pagès, Gilles, additional

Published
2023
Full Text
View/download PDF

8. Supplementary Figure Legends from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, primary, Ambrosetti, Damien, primary, Claren, Audrey, primary, Ndiaye, Papa Diogop, primary, Mastri, Michalis, primary, Moghrabi, Walid, primary, Cooley, Lindsay S., primary, Ettaiche, Marc, primary, Chamorey, Emmanuel, primary, Parola, Julien, primary, Vial, Valerie, primary, Lupu-Plesu, Marilena, primary, Bernhard, Jean Christophe, primary, Ravaud, Alain, primary, Borchiellini, Delphine, primary, Ferrero, Jean-Marc, primary, Bikfalvi, Andréas, primary, Ebos, John M., primary, Khabar, Khalid Saad, primary, Grépin, Renaud, primary, and Pagès, Gilles, primary

Published
2023
Full Text
View/download PDF

9. Supplemental Figure S3 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, primary, Ambrosetti, Damien, primary, Claren, Audrey, primary, Ndiaye, Papa Diogop, primary, Mastri, Michalis, primary, Moghrabi, Walid, primary, Cooley, Lindsay S., primary, Ettaiche, Marc, primary, Chamorey, Emmanuel, primary, Parola, Julien, primary, Vial, Valerie, primary, Lupu-Plesu, Marilena, primary, Bernhard, Jean Christophe, primary, Ravaud, Alain, primary, Borchiellini, Delphine, primary, Ferrero, Jean-Marc, primary, Bikfalvi, Andréas, primary, Ebos, John M., primary, Khabar, Khalid Saad, primary, Grépin, Renaud, primary, and Pagès, Gilles, primary

Published
2023
Full Text
View/download PDF

10. Data from PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness

Author

Kaminski, Lisa, primary, Torrino, Stéphanie, primary, Dufies, Maeva, primary, Djabari, Zied, primary, Haider, Romain, primary, Roustan, François-René, primary, Jaune, Emilie, primary, Laurent, Kathiane, primary, Nottet, Nicolas, primary, Michiels, Jean-François, primary, Gesson, Maeva, primary, Rocchi, Stéphane, primary, Mazure, Nathalie M., primary, Durand, Matthieu, primary, Tanti, Jean-François, primary, Ambrosetti, Damien, primary, Clavel, Stephan, primary, Ben-Sahra, Issam, primary, and Bost, Frédéric, primary

Published
2023
Full Text
View/download PDF

11. Supplemental Figure 1 from Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

Author

Grosso, Sébastien, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Colosetti, Pascal, primary, Jacquel, Arnaud, primary, Lebrigand, Kevin, primary, Barbry, Pascal, primary, Deckert, Marcel, primary, Cassuto, Jill Patrice, primary, Mari, Bernard, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

12. Data from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, primary, Ambrosetti, Damien, primary, Claren, Audrey, primary, Ndiaye, Papa Diogop, primary, Mastri, Michalis, primary, Moghrabi, Walid, primary, Cooley, Lindsay S., primary, Ettaiche, Marc, primary, Chamorey, Emmanuel, primary, Parola, Julien, primary, Vial, Valerie, primary, Lupu-Plesu, Marilena, primary, Bernhard, Jean Christophe, primary, Ravaud, Alain, primary, Borchiellini, Delphine, primary, Ferrero, Jean-Marc, primary, Bikfalvi, Andréas, primary, Ebos, John M., primary, Khabar, Khalid Saad, primary, Grépin, Renaud, primary, and Pagès, Gilles, primary

Published
2023
Full Text
View/download PDF

13. Figure S3 from PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness

Author

Kaminski, Lisa, primary, Torrino, Stéphanie, primary, Dufies, Maeva, primary, Djabari, Zied, primary, Haider, Romain, primary, Roustan, François-René, primary, Jaune, Emilie, primary, Laurent, Kathiane, primary, Nottet, Nicolas, primary, Michiels, Jean-François, primary, Gesson, Maeva, primary, Rocchi, Stéphane, primary, Mazure, Nathalie M., primary, Durand, Matthieu, primary, Tanti, Jean-François, primary, Ambrosetti, Damien, primary, Clavel, Stephan, primary, Ben-Sahra, Issam, primary, and Bost, Frédéric, primary

Published
2023
Full Text
View/download PDF

14. Supplemental Table S1 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, primary, Ambrosetti, Damien, primary, Claren, Audrey, primary, Ndiaye, Papa Diogop, primary, Mastri, Michalis, primary, Moghrabi, Walid, primary, Cooley, Lindsay S., primary, Ettaiche, Marc, primary, Chamorey, Emmanuel, primary, Parola, Julien, primary, Vial, Valerie, primary, Lupu-Plesu, Marilena, primary, Bernhard, Jean Christophe, primary, Ravaud, Alain, primary, Borchiellini, Delphine, primary, Ferrero, Jean-Marc, primary, Bikfalvi, Andréas, primary, Ebos, John M., primary, Khabar, Khalid Saad, primary, Grépin, Renaud, primary, and Pagès, Gilles, primary

Published
2023
Full Text
View/download PDF

15. Supplemental Table 1 from Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

Author

Grosso, Sébastien, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Colosetti, Pascal, primary, Jacquel, Arnaud, primary, Lebrigand, Kevin, primary, Barbry, Pascal, primary, Deckert, Marcel, primary, Cassuto, Jill Patrice, primary, Mari, Bernard, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data from PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness

Author

Kaminski, Lisa, primary, Torrino, Stéphanie, primary, Dufies, Maeva, primary, Djabari, Zied, primary, Haider, Romain, primary, Roustan, François-René, primary, Jaune, Emilie, primary, Laurent, Kathiane, primary, Nottet, Nicolas, primary, Michiels, Jean-François, primary, Gesson, Maeva, primary, Rocchi, Stéphane, primary, Mazure, Nathalie M., primary, Durand, Matthieu, primary, Tanti, Jean-François, primary, Ambrosetti, Damien, primary, Clavel, Stephan, primary, Ben-Sahra, Issam, primary, and Bost, Frédéric, primary

Published
2023
Full Text
View/download PDF

17. Data from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

Author

Fenouille, Nina, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Robert, Guillaume, primary, Jacquel, Arnaud, primary, Ohanna, Mickaël, primary, Deckert, Marcel, primary, Pasquet, Jean-Max, primary, Mahon, François-Xavier, primary, Cassuto, Jill-Patrice, primary, Raynaud, Sophie, primary, Tartare-Deckert, Sophie, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figures 1-6 from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

Author

Fenouille, Nina, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Robert, Guillaume, primary, Jacquel, Arnaud, primary, Ohanna, Mickaël, primary, Deckert, Marcel, primary, Pasquet, Jean-Max, primary, Mahon, François-Xavier, primary, Cassuto, Jill-Patrice, primary, Raynaud, Sophie, primary, Tartare-Deckert, Sophie, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Methods from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

Author

Fenouille, Nina, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Robert, Guillaume, primary, Jacquel, Arnaud, primary, Ohanna, Mickaël, primary, Deckert, Marcel, primary, Pasquet, Jean-Max, primary, Mahon, François-Xavier, primary, Cassuto, Jill-Patrice, primary, Raynaud, Sophie, primary, Tartare-Deckert, Sophie, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure Legends 1-6 from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

Author

Fenouille, Nina, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Robert, Guillaume, primary, Jacquel, Arnaud, primary, Ohanna, Mickaël, primary, Deckert, Marcel, primary, Pasquet, Jean-Max, primary, Mahon, François-Xavier, primary, Cassuto, Jill-Patrice, primary, Raynaud, Sophie, primary, Tartare-Deckert, Sophie, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

22. Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas

Author

Penco-Campillo, Manon, primary, Molina, Clément, additional, Piris, Patricia, additional, Soufi, Nouha, additional, Carré, Manon, additional, Pagnuzzi-Boncompagni, Marina, additional, Picco, Vincent, additional, Dufies, Maeva, additional, Ronco, Cyril, additional, Benhida, Rachid, additional, Martial, Sonia, additional, and Pagès, Gilles, additional

Published
2022
Full Text
View/download PDF

23. New splice variants of VEGF as relevant targets for the treatment of renal cell carcinoma

Author

Montemagno, Christopher, primary, Durivault, Jérôme, additional, Gastaldi, Cécile, additional, Dufies, Maeva, additional, Vial, Valérie, additional, He, Xingkang, additional, Ambrosetti, Damien, additional, Kamenskaya, Anna, additional, Négrier, Sylvie, additional, Bernhard, Jean Christophe, additional, Borchiellini, Delphine, additional, Cao, Yihai, additional, and Pagès, Gilles, additional

Published
2022
Full Text
View/download PDF

24. Cancer‐associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti‐angiogenic therapy.

Author

Ambrosetti, Damien, Coutts, Michael, Paoli, Charlotte, Durand, Matthieu, Borchiellini, Delphine, Montemagno, Christopher, Rastoin, Olivia, Borderie, Arnaud, Grepin, Renaud, Rioux‐Leclercq, Nathalie, Bernhard, Jean‐Christophe, Pagès, Gilles, and Dufies, Maeva

Subjects
RENAL cell carcinoma, NEOVASCULARIZATION inhibitors, VASCULAR endothelial growth factors, FIBROBLASTS, LYMPHATIC metastasis, PROGNOSIS
Abstract

Objectives: To investigate the role of cancer‐associated fibroblasts (CAFs) in clear cell renal cell carcinoma (ccRCC) with respect to tumour aggressiveness, metastasis development, and resistance to anti‐angiogenic therapy (vascular endothelial growth factor receptor‐tyrosine kinase inhibitors [VEGFR‐TKI]). Patients and Methods: Our study involved tissue samples from three distinct and independent cohorts of patients with ccRCC. The presence of CAFs and tumour lymphangiogenesis was investigated, respectively, by transcriptional signatures and then correlated with tumour development and prognosis. The effect of these CAFs on tumour cell migration and VEGFR‐TKI resistance was analysed on co‐cultures of ccRCC cells with CAFs. Results: Results from our cohorts and from in silico investigations showed that VEGFR‐TKI significantly increase the number of CAFs in tumours. In the same populations of patients with ccRCC, the proportion of intra‐tumoral CAFs correlated to shorter disease‐free and overall survival. The presence of CAFs was also correlated with lymphangiogenesis and lymph node metastasis. CAFs increased the migration and decreased the VEGFR‐TKI‐dependent cytotoxic effect of tumour cells. Conclusions: Our results show that VEGFR‐TKI promote the development of CAFs, and CAFs favour tumour aggressiveness, metastatic dissemination, and resistance to treatment in ccRCC. CAFs could represent a new therapeutic target to fight resistance to treatment of ccRCC. Targeting CAF and immunotherapies combination are emerging as efficient treatments in many types of solid tumours. Our results highlight their relevance in ccRCC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR + CXCL-CXCR1/2 Pathway Inhibitor.

Author

Grytsai O, Dufies M, Le Du J, Rastoin O, Pires Gonçalves LC, Mateo L, Lacas-Gervais S, Cao Y, Demange L, Pagès G, Benhida R, and Ronco C

Abstract

CXCR1/2 biomolecules play vital roles in cancer cell proliferation, tumor inflammation, and angiogenesis, making them attractive drug targets. In clear cell renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC), where CXCR1/2 is overexpressed, inhibition studies are limited. Building upon previous research efforts, we investigated new N , N '-diarylurea analogues as ELR + CXCL-CXCR1/2 inhibitors. Evaluations on RCC and HNSCC cell lines and 3D spheroid cultures identified compound 10 as a lead molecule, exhibiting significant inhibition of invasion, migration, and neo-angiogenesis. It demonstrated strong interference with the signaling pathway, with high selectivity toward kinases. In vivo studies on zebrafish embryos and RCC xenografted mice showed notable anticancer, antimetastatic, and antiangiogenic effects after oral administration and minimal toxicity. Compound 10 emerges as a promising candidate for further preclinical development as an oral anticancer and antiangiogenic drug targeting the ELR + CXCL-CXCR1/2 pathway., Competing Interests: The authors declare the following competing financial interest(s): L.C.P.G. reports financial support was provided by Roca Therapeutics. O.R. reports financial support was provided by Roca Therapeutics. J.L.D. reports financial support was provided by Roca Therapeutics. M.D. reports a relationship with Roca Therapeutics that includes: board membership. G.P. reports a relationship with Roca Therapeutics that includes: board membership. R.B. reports a relationship with Roca Therapeutics that includes: board membership. C.R. reports a relationship with Roca Therapeutics that includes: board membership. M.D. has Patent WO2020079184A2 licensed to Roca Therapeutics. G.P. has Patent WO2020079184A2 pending to Roca Therapeutics. R.B. has Patent WO2020079184A2 licensed to Roca Therapeutics. C.R. has Patent WO2020079184A2 licensed to Roca Therapeutics. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 American Chemical Society.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results